Stein Steven H 4

What Happened

• Steven H. Stein, EVP and Chief Medical Officer of Incyte Corp (INCY), received a grant/award of derivative securities covering 19,932 shares on January 16, 2026. The Form 4 reports an acquisition price of $0.00 and classifies the transaction as an award/derivative (code A).
• This is an equity award (options per the filing footnote), not an open‑market purchase or sale—so it reflects compensation/award rather than an immediate bullish or bearish trade.

Key Details

• Transaction date: 2026-01-16; filing date: 2026-01-21.
• Amount: 19,932 derivative shares; reported price: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Beginning Jan 16, 2026, the options become exercisable in 37 installments — first 25% vests on July 15, 2026; the remainder vests monthly over the next three years (per footnote F1).
• No 10b5-1 plan, tax‑withholding sale, or immediate cashless exercise is indicated in the provided details.

Context

• Because this is an award of options (derivative securities) tied to future vesting/exercise, it does not represent an immediate purchase of stock or sale of holdings. Such grants are common as part of executive compensation and do not by themselves signal near‑term market action.